IMO-2125, Yervoy Combo is on Fast Track for Treating Refractory Metastatic Melanoma

IMO-2125, Yervoy Combo is on Fast Track for Treating Refractory Metastatic Melanoma

The U.S. Food and Drug Administration (FDA) granted fast track status to Idera Pharmaceuticals‘ IMO-2125, in combination with Yervoy (ipilimumab), for the treatment of metastatic melanoma patients whose disease progressed after anti-PD-1 therapy.

The new designation is meant to expedite the clinical development of the combination therapy. It follows the orphan drug designation granted to IMO-2125 in June for the treatment of stage 2b-4 melanoma.

“This Fast Track designation represents another positive step for the development of IMO-2125 and is a clear recognition of the serious unmet need that exists for patients who do not benefit from anti-PD-1 therapy,” Joanna Horobin, chief medical officer at Idera, said in a press release.

Idera’s IMO-2125 was made to activate the toll-like receptor 9 (TLR9), a molecule that is found in dendritic and B-cells. Its activation triggers immune-signaling cascades that boost the anti-cancer activity of T cells.

Based on its unique activity, IMO-2125 represents a new strategy to boost immune responses and treat solid cancers that do not respond to immune checkpoint inhibitors such as anti-PD-1 drugs.

Results presented in September at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference revealed that IMO-2125 plus Yervoy significantly reduced tumor size and induced sustained anti-tumor immune responses in mice.

The effects were seen both in tumors that received a IMO-2125 injection and in distant tumors. Also, when mice were challenged with cancer cells for a second time they were able to completely clear any traces of cancer without the need of additional therapies.

Currently, IMO-2125 is being evaluated in a Phase 1/2 trial (NCT02644967) in combination with Yervoy or Keytruda (pembrolizumab) for the treatment of metastatic melanoma.

Results from the first 18 patients treated with IMO-2125 plus Yervoy have shown that intratumoral IMO-2125 plus Yervoy is well-tolerated and promotes anti-tumor immune responses.

“We’re thrilled with the dramatic response rate that has been observed so far with IMO-2125 in combination with ipilimumab and are eager to continue enrolling more patients through both the Phase 2 expansion of our ongoing trial and initiating the Phase 3 trial early next year,” Horobin said.

IMO-2125 also is being tested in additional refractory tumors in a U.S.-based Phase 1 trial (NCT03052205). Those interested in participating may contact the company by email ([email protected]).

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?